ClinicalTrials.Veeva

Menu
T

Texas Institute for Kidney and Endocrine Disorders | Lufkin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
LY3298176
MK-2060
LY900014
Evolocumab
BI 690517
Canagliflozin
Tirzepatide
Retatrutide
BI 685509

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 10 total trials

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling
Kidney Disease, Chronic
Drug: Placebo matching BI 690517
Drug: Empagliflozin

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo
Locations recently updated

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Lilly logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems